 CAMBRIDGE, Mass., Nov. 03, 2021 GLOBE NEWSWIRE -- Fulcrum Therapeutics, Inc. Nasdaq: FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences: 